| Year |
Citation |
Score |
| 2021 |
Marquez-Ortiz RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, Kwak G, Littrell Z, Costello JC, Sreekanth V, Ormond DR, Karam SD, Kabos P, Cittelly DM. IL13Rα2 promotes proliferation and outgrowth of breast cancer brain metastases. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34544797 DOI: 10.1158/1078-0432.CCR-21-0361 |
0.312 |
|
| 2020 |
Valiente M, Van Swearingen AED, Anders CK, Bairoch A, Boire A, Bos PD, Cittelly DM, Erez N, Ferraro GB, Fukumura D, Gril B, Herlyn M, Holmen SL, Jain RK, Joyce JA, et al. Brain Metastasis Cell Lines Panel: a public resource of organotropic cell lines. Cancer Research. PMID 32641416 DOI: 10.1158/0008-5472.Can-20-0291 |
0.348 |
|
| 2020 |
Bhatia S, Bukkapatnam S, Van Court B, Phan A, Oweida A, Gadwa J, Mueller AC, Piper M, Darragh L, Nguyen D, Gilani A, Knitz M, Bickett T, Green A, Venkataraman S, ... ... Cittelly D, et al. The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme. Molecular Carcinogenesis. PMID 32567728 DOI: 10.1002/Mc.23237 |
0.365 |
|
| 2020 |
Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, Messersmith WA, Eckhardt SG, Diamond JR. Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. Cancers. 12. PMID 32204315 DOI: 10.3390/Cancers12030719 |
0.414 |
|
| 2020 |
Brechbuhl HM, Barrett AS, Kopin E, Hagen JC, Han AL, Gillen AE, Finlay-Schultz J, Cittelly DM, Owens P, Horwitz KB, Sartorius CA, Hansen KC, Kabos P. Fibroblast subtypes define a metastatic matrisome in breast cancer. Jci Insight. PMID 32045383 DOI: 10.1172/Jci.Insight.130751 |
0.422 |
|
| 2020 |
Marquez-Ortiz RA, Contreras-Zarate MJ, Day NL, Ormond R, Borges VF, Cittelly DM. Abstract P6-05-04: Ligand dependent and independent roles of interleukin-13 receptor alpha 2 in breast cancer brain metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-05-04 |
0.37 |
|
| 2020 |
Contreras-Zárate MJ, Lai S, Stumpf P, Fisher C, Ormond R, Karam SD, Kabos P, Cittelly DM. Abstract P5-14-20: Mechanisms of radiation-induced brain edema alone and in combination with T-DM1 in Her2+ brain metastases Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-14-20 |
0.365 |
|
| 2020 |
Cittelly DM, Contreras-Zarate MJ, Marquez-Ortiz RA, Day N, Nagle B, Ormond R, Borges VF, Kabos P. Abstract P2-20-03: Estrogen-depletion therapies prevent and delay progression of brain metastasis Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-20-03 |
0.347 |
|
| 2019 |
Yamamoto TM, McMellen A, Watson ZL, Aguilera J, Ferguson R, Nurmemmedov E, Thakar T, Moldovan GL, Kim H, Cittelly DM, Joglar AM, Brennecke EP, Wilson H, Behbakht K, Sikora MJ, et al. Activation of Wnt signaling promotes olaparib resistant ovarian cancer. Molecular Carcinogenesis. PMID 31219654 DOI: 10.1002/Mc.23064 |
0.33 |
|
| 2019 |
Stumpf PK, Cittelly DM, Robin TP, Carlson JA, Stuhr KA, Contreras-Zarate MJ, Lai S, Ormond DR, Rusthoven CG, Gaspar LE, Rabinovitch R, Kavanagh BD, Liu A, Diamond JR, Kabos P, et al. Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of Aquaporin-4. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30940654 DOI: 10.1158/1078-0432.Ccr-18-2851 |
0.336 |
|
| 2019 |
Contreras-Zárate MJ, Day NL, Ormond DR, Borges VF, Tobet S, Gril B, Steeg PS, Cittelly DM. Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases. Oncogene. PMID 30796353 DOI: 10.1038/S41388-019-0756-Z |
0.428 |
|
| 2018 |
Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, DeGala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. Molecular Cancer Research : McR. PMID 30213797 DOI: 10.1158/1541-7786.Mcr-18-0246 |
0.41 |
|
| 2018 |
Just NP, Finlay-Schultz J, Gillen AE, Cittelly DM, Wellberg EA, Horwitz KB, Kabos P, Sartorius CA. Abstract 3027: Single-cell RNA sequencing defines regulatory networks in ER+ breast cancer organ-specific metastases Tumor Biology. DOI: 10.1158/1538-7445.Am2018-3027 |
0.359 |
|
| 2017 |
Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM. Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Frontiers in Oncology. 7: 252. PMID 29164052 DOI: 10.3389/Fonc.2017.00252 |
0.422 |
|
| 2016 |
Hanna C, Kwok L, Finlay-Schultz J, Sartorius CA, Cittelly DM. Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. Journal of Visualized Experiments : Jove. PMID 27929464 DOI: 10.3791/54944 |
0.375 |
|
| 2016 |
Brechbuhl HM, Finlay-Schultz J, Yamamoto T, Gillen A, Cittelly DM, Tan AC, Sams SB, Pillai M, Elias A, Robinson WA, Sartorius CA, Kabos P. Fibroblast subtypes regulate responsiveness of luminal breast cancer to estrogen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27702820 DOI: 10.1158/1078-0432.Ccr-15-2851 |
0.441 |
|
| 2016 |
Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer Expression in Estrogen Receptor Positive versus Triple-Negative Breast Cancer: An Antibody Comparison. Human Pathology. PMID 27260947 DOI: 10.1016/J.Humpath.2016.05.014 |
0.425 |
|
| 2016 |
Hanna C, Jacobsen BM, Sartorius CA, Kabos P, Lillehei K, Ormond DR, Graner M, Borges VF, Cittelly DM. Abstract A09: Development of novel breast cancer brain-metastases-derived xenografts and cell lines Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-A09 |
0.424 |
|
| 2015 |
Sartorius CA, Hanna CT, Gril B, Cruz H, Serkova NJ, Huber KM, Kabos P, Schedin TB, Borges VF, Steeg PS, Cittelly DM. Estrogen promotes the brain metastatic colonization of triple negative breast cancer cells via an astrocyte-mediated paracrine mechanism. Oncogene. PMID 26411365 DOI: 10.1038/Onc.2015.353 |
0.456 |
|
| 2015 |
Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 34: 3676-87. PMID 25241899 DOI: 10.1038/Onc.2014.298 |
0.408 |
|
| 2015 |
Cittelly DM, Cruz H, Serkova NJ, Virginia BF, Peter K, Patricia SS, Carol SA. Abstract P4-04-04: Estrogen signaling through astrocytes promotes migration and invasion of ER-negative brain metastatic breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-04-04 |
0.453 |
|
| 2014 |
Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research : Bcr. 16: R7. PMID 24451109 DOI: 10.1186/Bcr3599 |
0.414 |
|
| 2013 |
Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4 Oncogene. 32: 2555-2564. PMID 22751119 DOI: 10.1038/Onc.2012.275 |
0.431 |
|
| 2013 |
Cittelly DM, Cochrane DR, Howe EN, Dimitrova I, Post MD, Russell BR, Spillman MA, Richer JK. Abstract B70: Decreasing ovarian cancer metastases and progression via restoration of microRNAs that target mediators of anoikis- and chemoresistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-B70 |
0.383 |
|
| 2012 |
Howe EN, Cochrane DR, Cittelly DM, Richer JK. miR-200c Targets a NF-κB Up-Regulated TrkB/NTF3 Autocrine Signaling Loop to Enhance Anoikis Sensitivity in Triple Negative Breast Cancer Plos One. 7. PMID 23185507 DOI: 10.1371/Journal.Pone.0049987 |
0.441 |
|
| 2012 |
Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Molecular Cancer Therapeutics. 11: 2556-65. PMID 23074172 DOI: 10.1158/1535-7163.Mct-12-0463 |
0.348 |
|
| 2012 |
Elias AD, Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Protter AA, Richer JK. Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts. Journal of Clinical Oncology. 30: 564-564. DOI: 10.1200/Jco.2012.30.15_Suppl.564 |
0.441 |
|
| 2012 |
Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Elias AD, Richer JK. Abstract LB-109: MDV3100, an androgen receptor signaling inhibitor, inhibits tumor growth in breast cancer preclinical models regardless of estrogen receptor status Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-109 |
0.441 |
|
| 2010 |
Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer Hormones and Cancer. 1: 306-319. PMID 21761362 DOI: 10.1007/S12672-010-0043-5 |
0.37 |
|
| 2010 |
Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer. 9: 317. PMID 21172025 DOI: 10.1186/1476-4598-9-317 |
0.413 |
|
| 2010 |
Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE. Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 31: 2049-57. PMID 20876285 DOI: 10.1093/Carcin/Bgq192 |
0.438 |
|
| 2010 |
Cittelly DM, Richer JK, Sartorius CA. Ovarian steroid hormones: what's hot in the stem cell pool? Breast Cancer Research : Bcr. 12: 309. PMID 20825628 DOI: 10.1186/Bcr2627 |
0.345 |
|
| 2008 |
Cittelly DM, Nesic O, Johnson K, Hulsebosch C, Perez-Polo JR. Detrimental effects of antiapoptotic treatments in spinal cord injury. Experimental Neurology. 210: 295-307. PMID 18302959 DOI: 10.1016/J.Expneurol.2007.03.001 |
0.519 |
|
| 2007 |
Cittelly DM, Nesic-Taylor O, Perez-Polo JR. Phosphorylation of Bcl-xL after spinal cord injury. Journal of Neuroscience Research. 85: 1894-911. PMID 17551978 DOI: 10.1002/Jnr.21313 |
0.481 |
|
| 2007 |
Cittelly DM, Perez-Polo JR. Antiapoptotic therapies in the treatment of spinal cord injury Future Neurology. 2: 425-434. DOI: 10.2217/14796708.2.4.425 |
0.517 |
|
| 2005 |
Nesic-Taylor O, Cittelly D, Ye Z, Xu GY, Unabia G, Lee JC, Svrakic NM, Liu XH, Youle RJ, Wood TG, McAdoo D, Westlund KN, Hulsebosch CE, Perez-Polo JR. Exogenous Bcl-xL fusion protein spares neurons after spinal cord injury. Journal of Neuroscience Research. 79: 628-37. PMID 15668909 DOI: 10.1002/Jnr.20400 |
0.517 |
|
| Show low-probability matches. |